Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enzastaurin (LY317615), a protein kinase Cβ inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines

1 Jul 2006

Abstract excerpt

Enzastaurin (LY317615), an acyclic bisindolylmaleimide, is an oral inhibitor of the protein kinase Cbeta isozyme. The objective of this study was to assess the efficacy of enzastaurin in inducing apoptosis in multiple myeloma (MM) cell lines and to investigate possible mechanisms of apoptosis. Cell proliferation assays were done on a variety of MM cell lines with unique characteristics (dexamethasone sensitive,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to PI3K/AKT/mTOR signaling in cancer
Share to Protein Kinase Regulation and GTPase Signaling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16891464
DOI: 10.1158/1535-7163.mct-05-0465

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enzastaurin (LY317615), a protein kinase Cβ inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell linesPMID 16891464Read ↗

Small-molecule HDAC and Akt Inhibitors Suppress Tumor Growth and Enhance Immunotherapy in Multiple MyelomaSemantic proximity Read ↗

The HDAC Inhibitor LBH589 Enhances the Antimyeloma Effects of the IGF-1RTK Inhibitor PicropodophyllinSemantic proximity Read ↗

Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cellsSemantic proximity Read ↗

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.Semantic proximity Read ↗

Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myelomaSemantic proximity Read ↗

The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.Semantic proximity Read ↗

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myelomaSemantic proximity Read ↗

The effect of azacitidine on interleukin-6 signaling and nuclear factor- B activation and its in vitro and in vivo activity against multiple myelomaSemantic proximity Read ↗

Growth control of multiple myeloma cells through inhibition of glycogen synthase kinase-3Semantic proximity Read ↗

Activating mutations in STAT3 and STAT5 differentially affect cellular proliferation and apoptotic resistance in multiple myeloma cells.Semantic proximity Read ↗

Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways.Semantic proximity Read ↗

A natural peptide, dolastatin 15, induces G2/M cell cycle arrest and apoptosis of human multiple myeloma cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.